China Medical System's Drug Granted Clinical Trials Approval; Shares Up Nearly 7%

MT Newswires

02/02

China Medical System's (SGX:8A8) drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the Singapore Exchange.

Shares of the medical solutions company surged nearly % in Monday trading.

Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.

The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2608305398"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608305398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608305398?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608305398","market":"sg","top_or_hot":-1,"title":"China Medical System's Drug Granted Clinical Trials Approval; Shares Up Nearly 7%","media":"MT Newswires","content":"<html><body><p> China Medical System's (SGX:8A8) drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Shares of the medical solutions company surged nearly % in Monday trading.</p><p>Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.</p><p>The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System's Drug Granted Clinical Trials Approval; Shares Up Nearly 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System's Drug Granted Clinical Trials Approval; Shares Up Nearly 7%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time smaller\">2026-02-02 14:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China Medical System's (SGX:8A8) drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Shares of the medical solutions company surged nearly % in Monday trading.</p><p>Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.</p><p>The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲藥業控股有限公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608305398","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608305398","pubTimestamp":1770013920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Medical System's  drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the Singapore Exchange.Shares of the medical solutions company surged nearly % in Monday trading.Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司","BK6079":"制药"},"translate_title":"康哲药业的药物获得临床试验批件；股价上涨近7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":0.9},"content_text":"China Medical System's (SGX:8A8) drug, CMS-D017, secured a clinical trials approval in China by the National Medical Products Administration, according to a Friday filing with the Singapore Exchange.Shares of the medical solutions company surged nearly % in Monday trading.Following the approval, the company will commence clinical trials in China to evaluate the safety, efficacy and other characteristics of the drug.The trial is seen as crucial in the group's efforts to enhance its capabilities in nephrology.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}